Plain-English translation of NCT07645469 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called FH-WT1-E50 TCR T cells for people with acute myeloid leukemia (a blood cancer) who still have a small amount of cancer remaining after their initial chemotherapy. The treatment works by taking your own immune cells from your blood, engineering them in a laboratory to recognize and attack leukemia cells, and then giving them back to you along with another medication called to help them work better.
Even after successful chemotherapy, many leukemia patients still have a small amount of cancer cells remaining in their bone marrow that can grow back and cause relapse. This trial is exploring whether engineered immune cells designed specifically to find and destroy these remaining cancer cells might prevent that relapse and improve long-term survival.
You likely qualify if…
You likely don't qualify if…
First, you'll undergo a procedure called leukapheresis where doctors collect immune cells from your blood over a few hours. After about 4 weeks, you'll receive chemotherapy infusions at the clinic, followed at least 4 weeks later by infusions of your engineered cells combined with more chemotherapy. You may receive a second round of treatment up to one year later if cells are available. Throughout the study, you'll have frequent blood draws, bone marrow biopsies, imaging scans, and heart function tests, with visits tapering over time—intensive monitoring for the first few months, then every 6 months for 5 years, and annually after that.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States